Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
| العنوان: | Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy |
|---|---|
| المؤلفون: | Gilda Cennamo, Daniela Montorio, Luca D’ Andrea, Antonio Farella, Elide Matano, Mario Giuliano, Raffaele Liuzzi, Maria Angelica Breve, Sabino De Placido, Giovanni Cennamo |
| المساهمون: | Cennamo, G., Montorio, D., D' Andrea, L., Farella, A., Matano, E., Giuliano, M., Liuzzi, R., Breve, M. A., De Placido, S. |
| المصدر: | Frontiers in Oncology, Vol 11 (2022) Frontiers in Oncology |
| بيانات النشر: | Frontiers Media SA, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | survival rate, Cancer Research, complications, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, complication, eye diseases, ruthenium-106 brachytherapy, Oncology, metastasis, metastasi, sense organs, uveal melanoma, local recurrence, RC254-282, Original Research |
| الوصف: | Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases, and patients’ survival rate during 4 years’ follow-up. A total of 355 eyes from 355 patients have been treated with Ru-106 plaque brachytherapy for uveal melanoma between February 2011 and March 2020. Five patients were lost to follow-up, and then 350 eyes of 350 patients (mean age 58 ± 11 years) were enrolled in this retrospective study. All patients underwent a complete ophthalmic examination including echography and spectral domain–optical coherence tomography. The mean follow-up was 4 years (3 months to 9 years). After treatment, the mean tumor thickness was reduced to 1.75 ± 0.21 mm. Radiation complications were found in 63% of patients: 38% showed radiation maculopathy, 11% had optic neuropathy, and 14% developed cataracts. Cancer-free survival was 99%, 97%, and 85%, respectively, at 5, 7, and 9 years. Ru-106 plaque brachytherapy represents a reliable treatment of uveal melanoma. This technique is valid and safe with a low rate of ocular complications during a long-term follow-up. |
| تدمد: | 2234-943X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad6acde1161a3a479ea944e5b865754bTest https://doi.org/10.3389/fonc.2021.754108Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ad6acde1161a3a479ea944e5b865754b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2234943X |
|---|